Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Financial targets

Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d after reimbursement and widespread insurance coverage is achieved (press release June 30, 2020)

The current size of the IMMray™ PanCan-d market is estimated to be USD 4.4 billion in the US and Europe.

Immunovia, Inc.’s first to market product, IMMray™ PanCan-d, is a long-sought solution for the unmet need of early and accurate detection of pancreatic cancer (PDAC).

Immunovia, Inc. has launched IMMray™ PanCan-d as a laboratory developed test exclusively available through Immunovia, Inc. in Massachusetts USA. For more information please visit:

Immunovia’s financial targets set forth above constitute forward-looking information and are based on a number of assumptions about the environment in which the Company operates, which may vary significantly and deteriorate over time from what Immunovia assessed when the financial targets were adopted. As a consequence, Immunovia’s ability to achieve the financial targets consists of uncertainties and contingencies, some of which are outside the Company’s control. There is no guarantee that Immunovia can achieve the financial targets or that Immunovia’s financial position or operating profit will not differ materially from the financial targets.

Immunovias financial targets